Milan, Italy

Giuseppe Legname

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Italfarmaco Spa. Active years: 1996.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Giuseppe Legname: Innovator in Ribosome Inactivating Proteins

Introduction

Giuseppe Legname is a notable inventor based in Milan, Italy. He has made significant contributions to the field of biotechnology, particularly in the area of ribosome inactivating proteins. His work has implications for various applications in medicine and agriculture.

Latest Patents

Giuseppe Legname holds a patent for nucleotide sequences coding for ribosome inactivating proteins. This patent represents a crucial advancement in understanding and utilizing these proteins for therapeutic purposes. He has 1 patent to his name, showcasing his innovative approach to biotechnology.

Career Highlights

Throughout his career, Legname has worked with esteemed organizations such as Italfarmaco Spa and Scuola Internazionale Superiore Di Studi Avanzati (SISSA). His experience in these institutions has allowed him to develop and refine his research in the field of ribosome inactivating proteins.

Collaborations

Giuseppe Legname has collaborated with notable colleagues, including Gianni Gromo and Daniela Modena. These partnerships have enriched his research and contributed to the advancement of knowledge in his area of expertise.

Conclusion

Giuseppe Legname's contributions to the field of biotechnology, particularly through his patent on ribosome inactivating proteins, highlight his role as an innovator. His collaborations and career experiences further emphasize his impact on the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…